Related Experiment Video
Updated: Jan 5, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Cytoreductive nephrectomy in the current treatment algorithm
Teele Kuusk1, Bernadett Szabados2, Wing Kin Liu3
1Royal Free Hospital, Department of Urology, Renal Cancer Unit, London, UK.
Abstract:
The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted therapy area, whereas SURTIME studied whether deferred CN in combination with sunitinib can be used to identify patients with inherent targeted therapy resistance. In the current review, we provide a comprehensive discussion of two randomized studies and the current evidence with up-do-date algorithms for treating primary metastatic clear-cell renal cell carcinoma in the era of targeted therapy and immune-checkpoint inhibition.
More Related Videos
06:39Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
Published on: November 22, 2019
07:11Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Chronic Kidney Disease III: Interprofessional Care
Continuous Renal Replacement Therapy
Acute Kidney Injury V: Interprofessional Care
Urinary Tract Calculi VI: Surgical Management